Dubai: Mohamad Saeed Al Raqbani, General Manager of Dubai Investments Industries and Board Director at Globalpharma, a subsidiary of Dubai Investments, confirmed that the company currently produces over 120 types of pharmaceuticals and exports its products to approximately 18 countries across Africa, the GCC, Eastern Europe, and Asia.
According to Emirates News Agency, Al Raqbani made these remarks on the sidelines of the fourth edition of the Make it in the Emirates forum. He stated that Globalpharma aims to expand its global footprint by adopting advanced technologies in the pharmaceutical industry and enhancing its competitiveness in international markets.
Al Raqbani emphasized that Globalpharma prioritizes the development of national talent through strategic partnerships with both local and international universities and institutions. These partnerships are aimed at training and empowering Emirati professionals in this vital and strategic sector.
He highlighted the company’s commitment to the highest global quality standards, having received the Pharmaceutical Quality Award at the Make it in the Emirates Awards. This accolade reflects Globalpharma’s ongoing dedication to excellence and innovation in the pharmaceutical industry.
Al Raqbani pointed out that the UAE’s investment in human capital is yielding positive results, as evidenced by the emergence of pioneering national talent and advanced industrial institutions that compete both regionally and globally.
Expressing pride in participating in the Make it in the Emirates forum, Al Raqbani noted that Globalpharma is committed to enhancing the UAE’s pharmaceutical security and delivering high-quality products that meet international standards. The company’s production includes a broad range of conventional and advanced medicines, and it is currently developing biological drugs and herbal products inspired by the UAE’s heritage.
Al Raqbani stressed that the pharmaceutical industry plays a strategic role in achieving self-sufficiency, with all of Globalpharma’s medicines being fully manufactured in the UAE at its facilities in Dubai Investments Park. He added that the Make it in the Emirates forum provides a key opportunity for the national industrial sector to connect with partners, showcase manufacturing capabilities, and explore cooperation and growth prospects both domestically and abroad.
He also revealed that Globalpharma signed four agreements during its participation in the forum with pharmaceutical manufacturers in Canada, Spain, and the Arab Republic of Egypt, as well as with an advanced pharmaceutical research center in Jordan. These agreements are part of the company’s efforts to expand its regional and international partnerships and strengthen its global presence through advanced pharmaceutical manufacturing that reflects the UAE’s leading position across various fields.